| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Terje Sagvolde. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behavioral and brain functions : BBF. vol 2. 2007-07-19. PMID:17173664. |
there is no biological marker, but there is considerable evidence to suggest that adhd behavior is associated with poor dopaminergic and noradrenergic modulation of neuronal circuits that involve the frontal lobes. |
2007-07-19 |
2023-08-12 |
rat |
| M Kopecková, I Paclt, P Goet. Polymorphisms of dopamine-beta-hydroxylase in ADHD children. Folia biologica. vol 52. issue 6. 2007-06-22. PMID:17184598. |
dysfunction or imbalance between the dopaminergic and noradrenergic systems of neurotransmitters can play a key role in the adhd pathophysiology. |
2007-06-22 |
2023-08-12 |
human |
| Vivienne Ann Russel. Neurobiology of animal models of attention-deficit hyperactivity disorder. Journal of neuroscience methods. vol 161. issue 2. 2007-06-12. PMID:17275916. |
however, evidence obtained from some animal models suggests that the noradrenergic and serotonergic neurotransmitter systems may be the target of drugs that ameliorate adhd symptoms. |
2007-06-12 |
2023-08-12 |
mouse |
| Neil Easton, Carolyn Steward, Fiona Marshall, Kevin Fone, Charles Marsde. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology. vol 52. issue 2. 2007-04-10. PMID:17020775. |
these results identify distinct pharmacological action by the amphetamine isomers on dopaminergic and noradrenergic neurotransmission, which may impact on their therapeutic effects in the treatment of adhd. |
2007-04-10 |
2023-08-12 |
rat |
| Xiaohui Xu, Keeley Brookes, Chih-Ken Chen, Yu-Shu Huang, Yu-Yu Wu, Philip Asherso. Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples. BMC psychiatry. vol 7. 2007-03-19. PMID:17328795. |
molecular genetic and pharmacological studies suggest the involvement of the dopaminergic, serotonergic and noradrenergic neurotransmitter systems in the pathogenesis of adhd. |
2007-03-19 |
2023-08-12 |
Not clear |
| Nora D Volkow, Gene-Jack Wang, Jeffrey Newcorn, Joanna S Fowler, Frank Telang, Mary V Solanto, Jean Logan, Christopher Wong, Yeming Ma, James M Swanson, Kurt Schulz, Kith Pradha. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. NeuroImage. vol 34. issue 3. 2007-03-15. PMID:17126039. |
it also provides evidence that dopamine transporter levels modulate attention but suggest that additional pathology (e.g., prefrontal or cingulostriatal pathways, noradrenergic neurotransmission) is necessary to account for the large differences in inattention observed between controls and adhd subjects. |
2007-03-15 |
2023-08-12 |
human |
| Mohammad Reza Mohammadi, Shahin Akhondzade. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert review of neurotherapeutics. vol 7. issue 2. 2007-02-27. PMID:17286552. |
several nonstimulant medications that affect noradrenergic and/or dopaminergic pathways have demonstrated efficacy in the treatment of adhd, although effect sizes are comparable with methylphenidate, fewer data have accumulated regarding the safety profile of nonstimulants in general. |
2007-02-27 |
2023-08-12 |
Not clear |
| David J Heal, David M Pierc. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS drugs. vol 20. issue 9. 2006-11-28. PMID:16953648. |
for these drugs, their abilities not only to ameliorate the behavioural and cognitive dysfunctions in adhd, but also to induce the common adverse effects of reduced appetite, nausea/vomiting and stomach ache, are almost certainly due to their ability to potentiate noradrenergic and/or dopaminergic function in the central and peripheral nervous systems. |
2006-11-28 |
2023-08-12 |
Not clear |
| Kristy J Bruno, Ellen J Hes. The alpha(2C)-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiology of disease. vol 23. issue 3. 2006-11-01. PMID:16839770. |
drugs that modify noradrenergic transmission such as atomoxetine and clonidine are increasingly prescribed for the treatment of attention deficit hyperactivity disorder (adhd). |
2006-11-01 |
2023-08-12 |
mouse |
| Philip Hazel. Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder? Expert opinion on pharmacotherapy. vol 6. issue 12. 2006-06-01. PMID:16197353. |
adrenergically active drugs used for the treatment of attention-deficit/hyperactivity disorder (adhd) include the alpha-agonists, monoamine oxidase inhibitors, tricyclics and the selective noradrenergic re-uptake inhibitors. |
2006-06-01 |
2023-08-12 |
Not clear |
| Bing Wang, Yufeng Wang, Rulun Zhou, Jun Li, Qiujin Qian, Li Yang, Lili Guan, Stephen V Faraon. Possible association of the alpha-2A adrenergic receptor gene (ADRA2A) with symptoms of attention-deficit/hyperactivity disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 141B. issue 2. 2006-05-01. PMID:16389583. |
a dysfunction of the central noradrenergic system has long been suggested to be involved in attention-deficit/hyperactivity disorder (adhd). |
2006-05-01 |
2023-08-12 |
Not clear |
| Caroly S Pataki, David T Feinberg, James J McGoug. New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert opinion on emerging drugs. vol 9. issue 2. 2006-02-24. PMID:15571486. |
atomoxetine, a selective noradrenergic re-uptake inhibitor, is the first non-stimulant compound to receive fda approval for paediatric and adult adhd. |
2006-02-24 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Ricardo Segurado, Judith Conroy, Karen Sheehan, Naomi Lowe, Aiveen Kirley, Denis Shields, Michael Fitzgerald, Louise Gallagher, Michael Gil. Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. American journal of human genetics. vol 77. issue 6. 2006-01-30. PMID:16380908. |
pharmacological, neuroimaging, and animal-model findings suggest imbalances in monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in adhd. |
2006-01-30 |
2023-08-12 |
Not clear |
| J Stevenson, K Langley, H Pay, A Payton, J Worthington, W Ollier, A Thapa. Attention deficit hyperactivity disorder with reading disabilities: preliminary genetic findings on the involvement of the ADRA2A gene. Journal of child psychology and psychiatry, and allied disciplines. vol 46. issue 10. 2005-12-23. PMID:16178932. |
neurobiological studies have implicated noradrenergic function in the aetiology of adhd that is comorbid with rd. |
2005-12-23 |
2023-08-12 |
Not clear |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
structural and functional imaging studies suggest that dysfunction in the fronto-subcortical pathways, as well as imbalances in the dopaminergic and noradrenergic systems, contribute to the pathophysiology of adhd. |
2005-07-29 |
2023-08-12 |
Not clear |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
medication with dopaminergic and noradrenergic activity seems to reduce adhd symptoms by blocking dopamine and norepinephrine reuptake. |
2005-07-29 |
2023-08-12 |
Not clear |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
such alterations in dopaminergic and noradrenergic function are apparently necessary for the clinical efficacy of pharmacologic treatments of adhd. |
2005-07-29 |
2023-08-12 |
Not clear |
| Bertha K Madras, Gregory M Miller, Alan J Fischma. The dopamine transporter and attention-deficit/hyperactivity disorder. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15950014. |
thus, adhd medications targeting dat or net might disperse dopamine widely and consign dopamine storage and release to regulation by noradrenergic, as well as dopaminergic neurons. |
2005-07-29 |
2023-08-12 |
human |
| Luis Augusto Rohde, Cláudia Szobot, Guilherme Polanczyk, Marcelo Schmitz, Silvia Martins, Silzá Tramontin. Attention-deficit/hyperactivity disorder in a diverse culture: do research and clinical findings support the notion of a cultural construct for the disorder? Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15950018. |
the prevalence rates of adhd (5.8% using dsm-iv criteria, 1.5% using icd-10), the bi-dimensional factor construct extracted from factor analyses (inattention and hyperactivity/impulsivity), the pattern of adhd comorbidity in clinical samples, the family genetic data suggesting a 39% family transmission in clinical samples and the role of some potential candidate genes in dopaminergic and noradrenergic systems, as well as data on the efficacy of methylphenidate in the disorder are all very similar to findings from developed countries. |
2005-07-29 |
2023-08-12 |
Not clear |
| Vivienne A Russell, Terje Sagvolden, Espen Borgå Johanse. Animal models of attention-deficit hyperactivity disorder. Behavioral and brain functions : BBF. vol 1. 2005-07-29. PMID:16022733. |
aspects of adhd behaviour may result from an imbalance between increased noradrenergic and decreased dopaminergic regulation of neural circuits that involve the prefrontal cortex. |
2005-07-29 |
2023-08-12 |
human |